FDA Lacks Legal Sway To Enforce AER Label Revisions – Attorney
This article was originally published in The Tan Sheet
There is little chance FDA will aggressively enforce changes to dietary supplement and OTC drug labels recommended in the adverse event report labeling guidance, a food and drug attorney says
You may also be interested in...
FDA's estimate of nearly $44 million for the dietary supplement industry to revise labels to comply with the adverse event reporting law may understate the actual burden by leaving out some key costs
FDA's recommendation for complete addresses on OTC and dietary supplement product labels in order to comply with the adverse event reporting law exceeds not only Congress's intent, but also the requirements for all other products regulated by the agency, industry groups say
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.